Oncolys BioPharma Balance Sheet Health
Financial Health criteria checks 5/6
Oncolys BioPharma has a total shareholder equity of ¥1.5B and total debt of ¥288.9M, which brings its debt-to-equity ratio to 19.6%. Its total assets and total liabilities are ¥2.0B and ¥566.5M respectively.
Key information
19.6%
Debt to equity ratio
JP¥288.88m
Debt
Interest coverage ratio | n/a |
Cash | JP¥1.53b |
Equity | JP¥1.47b |
Total liabilities | JP¥566.50m |
Total assets | JP¥2.04b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 4588's short term assets (¥2.0B) exceed its short term liabilities (¥378.5M).
Long Term Liabilities: 4588's short term assets (¥2.0B) exceed its long term liabilities (¥188.0M).
Debt to Equity History and Analysis
Debt Level: 4588 has more cash than its total debt.
Reducing Debt: 4588's debt to equity ratio has increased from 13.6% to 19.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4588 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4588 has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 10.3% each year.